Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

NCT04056897 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

271

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

BIOLOGICAL: BCD-132, 125 mg
DRUG: Teriflunomide
DRUG: Placebo
BIOLOGICAL: BCD-132, 500 mg

Sponsor

Biocad